Skip to main content
SpringerLink
Log in

Several approved biologic agents are now available to treat paediatric plaque psoriasis

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Off-label treatments are widely used in the treatment of paediatric psoriasis, which are prescribed on the basis of efficacy and safety data derived from studies in adult psoriasis patients or from paediatric patients with other diseases due to a lack of clinical trials in paediatric psoriasis patients. A growing number of treatments are being tested and approved for plaque psoriasis (the most common type of psoriasis) in paediatric patients, and they are predominantly biologic treatments. Depending on the country, approved biologic treatments for paediatric plaque psoriasis may include etanercept, adalimumab, ustekinumab, secukinumab and ixekizumab; though biologic treatments are reserved for more severe forms of psoriasis. Biologic treatments should be used under the supervision of a specialist, with support, advice and evidence-based information given to patients and their caregivers. For instance, warning patients about the potential for injection site reactions and infections. Furthermore, the importance of adherence to therapy should be emphasised to patients and their caregivers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bronckers IM, Paller AS, van Geel MJ, et al. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr Drugs. 2015;17(5):373–84.

    Article  CAS  Google Scholar 

  2. Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201.

    Article  Google Scholar 

  3. Nogueira M, Paller AS, Torres T. Targeted therapy for pediatric psoriasis. Pediatr Drugs. 2021;23(3):203–12.

    Article  Google Scholar 

  4. Haulrig MB, Zachariae C, Skov L. Off-label treatments for pediatric psoriasis: lessons for the clinic. Psoriasis (Auckl). 2021;11:1–20.

    PubMed  PubMed Central  Google Scholar 

  5. Immunex Corporation. Enbrel® (etanercept) injection, for subcutaneous use: US prescribing information. 2020.

  6. Mylan IRE Healthcare Limited. Nepexto® (etanercept) solution for injection: EU summary of product characteristics. 2021.

  7. Sandoz GmbH. Hyrimoz® (adalimumab): EU summary of product characteristics. 2021.

  8. Janssen Biotech, Inc. Stelara® (ustekinumab) injection, for subcutaneous or intravenous use: US prescribing information. 2020.

  9. Janssen-Cilag International NV. Stelara® (ustekinumab) solution for injection/solution for injection in pre-filled syringe: EU summary of product characteristics. 2021.

  10. Novartis. Cosentyx® (secukinumab) injection, for subcutaneous use: US prescribing information. 2021.

  11. Novartis Europharm Limited. Cosentyx® (secukinumab) solution for injection in pre-filled syringe: EU summary of product characteristics. 2021.

  12. Eli Lilly and Company. Taltz® (ixekizumab) injection, for subcutaneous use: US prescribing information. 2021.

  13. Eli Lilly and Company. Taltz® (ixekizumab) solution for injection in pre-filled syringe: EU summary of product characteristics. 2021.

  14. Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628–37.

    Article  CAS  Google Scholar 

  15. Pinter A, Mielke N, Malisiewicz B, et al. Management of paediatric psoriasis by paediatricians: a questionnaire-based survey. Dermatol Ther (Heidelb). 2020;10(4):671–80.

    Article  Google Scholar 

  16. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241–51.

    Article  CAS  Google Scholar 

  17. Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74(2):280–7.

    Article  CAS  Google Scholar 

  18. Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10089):40–9.

    Article  CAS  Google Scholar 

  19. Thaçi D, Papp K, Marcoux D, et al. Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. Br J Dermatol. 2019;181(6):1177–89.

    Article  Google Scholar 

  20. Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12–17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):P594-603.

    Article  Google Scholar 

  21. Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183(4):664–72.

    Article  CAS  Google Scholar 

  22. Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomised, controlled trial. J Eur Acad Dermatol Venereol. 2021;35(4):938–47.

    Article  CAS  Google Scholar 

  23. Paller AS, Seyger MMB, Alejandro Magariños G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231–41.

    Article  CAS  Google Scholar 

  24. Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 2010;132(6):942–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Esther S. Kim & Arnold Lee

Authors
  1. Esther S. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arnold Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arnold Lee.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

E.S. Kim, a contracted employee of Adis International Ltd/Springer Nature, and A. Lee, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, E.S., Lee, A. Several approved biologic agents are now available to treat paediatric plaque psoriasis. Drugs Ther Perspect 38, 72–76 (2022). https://doi.org/10.1007/s40267-022-00896-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-022-00896-9

Search

Navigation